News

Filter

Current filters:

CSL Behring

1 to 9 of 17 results

Highlights of EMA Pharmacovigilance unit meeting

09-11-2014

At its meeting last week, the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee…

BayerBiogen IdecCSL BehringEuropeHelixateHematologyKogenateNeurologicalPharmaceuticalRegulationTecfidera

CSL Behring to invest $450 million in capacity expansion

CSL Behring to invest $450 million in capacity expansion

08-10-2014

CSL Behring, a unit of Australia-headquartered CLS Limited, has today announced a multi-year, $450 million…

AlbuminAustraliaBehringCLS LimitedCSL BehringFinancialHealth Medical PharmaHematologyPharmaceuticalUSA

CSL opens Australian biotechnology manufacturing facility

09-05-2014

Leading Australian biotech firm CSL Limited has opened the CSL Behring Biotechnology manufacturing facility…

AustraliaBiotechnologyCSL BehringCSL LimitedHematologyProductionResearch

Benefits of Kogenate/Helixate NexGen outweigh risks, says EMA unit

Benefits of Kogenate/Helixate NexGen outweigh risks, says EMA unit

08-12-2013

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has reviewed the…

BayerCardio-vascularCSL BehringCSL LimitedEuropeHelixateHematologyKogenatePharmaceuticalRegulation

EMA approves fortnightly dosing option for CSL’s Hizentra

EMA approves fortnightly dosing option for CSL’s Hizentra

05-12-2013

Plasma-protein specialists CSL Behring, a subsidiary of Australia’s CSL Ltd (CSL: AX), announced today…

CSL BehringEuropeHizentraImmunologicalsPharmaceuticalRegulationUK

CSL Behring’s Hizentra approved in Japan for PID and SID

CSL Behring’s Hizentra approved in Japan for PID and SID

27-09-2013

The Japanese Ministry of Health, Labor and Welfare has approved Hizentra for the treatment of primary…

Asia-PacificCSL BehringHizentraImmunologicalsPharmaceuticalRare diseasesRegulation

US Senator seeks answers from drugmakers on providing required discounts

27-09-2013

US Senator Charles Grassley has written to two drug companies on behalf of an Iowa hospital that is not…

CSL BehringExparelHematologyKcentraNeurologicalNorth AmericaPacira PharmaceuticalsPharmaceuticalPoliticsPricing

CSL Behring's rIX-FP shows efficacy in severe hemophilia B

03-07-2013

Data presented by CSL Behring today (July 3) showed clinical efficacy of a once-weekly dosing regimen…

CSL BehringCSL LimitedPharmaceuticalResearch

1 to 9 of 17 results

COMPANY SPOTLIGHT

Menarini

Back to top